MCA logo
MCA logo

PUBLIC PORTAL

MEDICALLY REVIEWED

Tepotinib (Tepmetko) for METex14-altered NSCLC

lung cancer tepotinib (tepmetko)
Tepotinib (Tepmetko) was recently approved for the use of Non-Small Cell Lung Cancer (NSCLC). Find out about the Phase II VISION trial here.

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: